Shariaportfolio Inc. Makes New $5.30 Million Investment in Astera Labs, Inc. $ALAB

Shariaportfolio Inc. purchased a new position in Astera Labs, Inc. (NASDAQ:ALAB) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 48,398 shares of the company’s stock, valued at approximately $5,304,000. Astera Labs comprises 2.3% of Shariaportfolio Inc.’s investment portfolio, making the stock its 9th biggest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada increased its holdings in Astera Labs by 167.3% in the 1st quarter. Royal Bank of Canada now owns 152,453 shares of the company’s stock worth $9,097,000 after buying an additional 95,409 shares in the last quarter. AQR Capital Management LLC lifted its stake in Astera Labs by 213.4% during the 1st quarter. AQR Capital Management LLC now owns 11,391 shares of the company’s stock valued at $680,000 after acquiring an additional 7,756 shares during the period. Empowered Funds LLC boosted its holdings in shares of Astera Labs by 917.3% during the 1st quarter. Empowered Funds LLC now owns 4,639 shares of the company’s stock valued at $277,000 after acquiring an additional 4,183 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Astera Labs by 102.0% during the 2nd quarter. First Trust Advisors LP now owns 112,766 shares of the company’s stock valued at $10,196,000 after acquiring an additional 56,952 shares during the last quarter. Finally, Brown Advisory Inc. boosted its holdings in shares of Astera Labs by 54.9% during the 2nd quarter. Brown Advisory Inc. now owns 5,581 shares of the company’s stock valued at $505,000 after acquiring an additional 1,977 shares during the last quarter. 60.47% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Stefan A. Dyckerhoff sold 3,505 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $450.00, for a total value of $1,577,250.00. Following the completion of the sale, the director directly owned 57,466 shares in the company, valued at $25,859,700. This represents a 5.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Sanjay Gajendra sold 400,000 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $290.30, for a total value of $116,120,000.00. Following the completion of the transaction, the chief operating officer directly owned 5,064,213 shares in the company, valued at approximately $1,470,141,033.90. This represents a 7.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,676,845 shares of company stock worth $444,928,806. Company insiders own 10.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Citigroup reissued a “buy” rating on shares of Astera Labs in a report on Wednesday. Evercore restated an “outperform” rating and issued a $297.00 target price on shares of Astera Labs in a report on Tuesday, May 19th. TD Cowen lifted their target price on shares of Astera Labs from $225.00 to $425.00 and gave the stock a “hold” rating in a research report on Monday, July 13th. Morgan Stanley boosted their target price on shares of Astera Labs from $210.00 to $240.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $270.00 price target on shares of Astera Labs in a report on Wednesday, May 6th. Thirteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Astera Labs has an average rating of “Moderate Buy” and an average target price of $284.25.

Astera Labs Stock Performance

Shares of NASDAQ ALAB opened at $311.23 on Monday. The firm has a 50 day moving average of $359.97 and a 200 day moving average of $230.19. The firm has a market capitalization of $53.35 billion, a price-to-earnings ratio of 210.29, a price-to-earnings-growth ratio of 3.61 and a beta of 3.84. Astera Labs, Inc. has a 12-month low of $97.89 and a 12-month high of $499.48.

Astera Labs (NASDAQ:ALAB) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.07. Astera Labs had a net margin of 26.72% and a return on equity of 18.49%. The business had revenue of $308.36 million during the quarter, compared to analysts’ expectations of $292.19 million. During the same period in the prior year, the company earned $0.33 earnings per share. The firm’s revenue was up 93.5% on a year-over-year basis. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. Sell-side analysts predict that Astera Labs, Inc. will post 1.86 EPS for the current year.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.